BioLineRx Ltd.

NASDAQ: BLRX
Share price (1/8/25): $0.14
Market cap (1/8/25): $11.4 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/23 FY 2023 – amended

ended 12/31/23 FY 2023

ended 12/31/22 FY 2022

ended 12/31/21 FY 2021 – amended

ended 12/31/21 FY 2021

Prospectuses and Registrations Filter

Prospectus supplement for primary offering

Registration of securities for employees

Prospectus supplement for primary offering

Prospectus supplement for primary offering

Registration of securities for employees

Ownership Filter

Hong Seng Technology Ltd

Intracoastal Capital, LLC

Altium Capital Management LP

Novartis Pharma AG

Senvest Management, LLC

News Filter

Material disclosure

Announces $10 Million Registered Direct Offering

Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx and Ayrmid Ltd. Enter Into Exclusive License Agreement to Commercialize APHEXDA® (Motixafortide) Through Gamida Cell Ltd

On November 12, 2024, BioLineRx Ltd. (The “Company”) Received a Letter From Nasdaq Advising That the Company Had Been Granted a 180-Day Extension to May 12, 2025, to Regain Compliance With Nasdaq's Minimum $1.00 Bid Price Requirement

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Confidential treatment order

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC